Format

Send to

Choose Destination
BMC Cancer. 2016 Aug 12;16:634. doi: 10.1186/s12885-016-2657-7.

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.

Author information

1
Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.
2
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
3
Department of Surgery, Section of Radiology, Uppsala University, Uppsala, Sweden.
4
Novartis Sverige AB, Kemistvägen 1, 183 79, Täby, Sweden.
5
Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden. Gustav.Ullenhag@igp.uu.se.
6
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. Gustav.Ullenhag@igp.uu.se.

Abstract

BACKGROUND:

Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM.

CASE PRESENTATION:

We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a BRAF(V600E) mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a week and she experienced a progression free survival of four months.

CONCLUSIONS:

To our knowledge, this is the first described case of response to vemurafenib treatment in a patient with ocular melanoma.

KEYWORDS:

BRAF inhibitor; BRAF mutation; Conjunctival malignant melanoma; Ocular melanoma; Vemurafenib

PMID:
27520988
PMCID:
PMC4983009
DOI:
10.1186/s12885-016-2657-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center